Evidence map›Paper›PMID 37221092›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2023

Deconvolution of Plasma Pharmacokinetics from Dynamic Heart Imaging Data Obtained by Single Positron Emission Computed Tomography/Computed Tomography Imaging.

Zengtao Wang, Lushan Wang, Malik Ebbini, Geoffry L Curran, Paul H Min, Ronald A Siegel, Val J Lowe, Karunya K Kandimalla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zengtao WangDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).
Lushan WangDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).ORCID 0000-0003-2541-4536
Malik EbbiniDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).
Geoffry L CurranDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).
Paul H MinDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).
Ronald A SiegelDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).ORCID 0000-0002-9591-1282
Val J LoweDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.).
Karunya K KandimallaDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (Z.W., L.W., M.E., R.A.S., K.K.K.) and Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota (G.L.C., P.H.M., V.J.L.) kkandima@umn.edu.

Funding

Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the blood brain barrierR01NS125437 · NINDS · UNIVERSITY OF MINNESOTA · PI KARUNYA KUMAR KANDIMALLA, VAL JOHN LOWE · 2022 to 2026
$2.6M
NINDS NIH HHS R01 NS125437
6 · The paper itself

Abstract

Plasma pharmacokinetic (PK) data are required as an input function for graphical analysis of single positron emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/CT (PET/CT) data to evaluate tissue influx rate of radiotracers. Dynamic heart imaging data are often used as a surrogate of plasma PK. However, accumulation of radiolabel in the heart tissue may cause overprediction of plasma PK. Therefore, we developed a compartmental model, which involves forcing functions to describe intact and degraded radiolabeled proteins in plasma and their accumulation in heart tissue, to deconvolve plasma PK of

Indexed as

InsulinsPositron Emission Tomography Computed TomographyAmyloid beta-PeptidesAnimalsElectronsIodine RadioisotopesMicePositron-Emission TomographyTomography, X-Ray ComputedAmyloid beta-PeptidesInsulinsIodine-125Iodine Radioisotopes

Identifiers

PMID37221092
PMCPMC10289239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.